|
|
|
|
Chronic Myeloid Leukaemia News Headlines
|
|
|
|
|
|
|
All Recent Chronic Myeloid Leukaemia News Headlines |
|
|
|
|
Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines
Conclusions: These data confirm that the intrachromosomal genomic amplification of BCR/ABL1 that occurs in some CML patients during disease progression also involves amplification of 9q34 gene-rich sequences downstream of ABL1 breakpoint. The variety of rearrangements identified in this relatively small cohort demonstrates that the Ph chromosome is not a stable structure but prone to further rearrangements during disease progression. (Source: Molecular Cytogenetics)...
POSTED 08/31/2010 at 06:00 PM --
|
Overdose with 16,000mg of imatinib mesylate
We report on a 53 years old woman, who ingested 16,000mg in a suicide attempt. (Source: Leukemia Research)...
POSTED 08/27/2010 at 01:28 AM --
|
ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma
A 30-year-old Caucasian male has been referred to our institution in June 2009 because for 3 months he presented recurrent fever, night sweats and asthenia. Nine years before the patient has been diagnosed with nodular sclerosis classical HL; at that time a computer tomography (CT) scan demonstrated a mediastinal bulky, epatho-splenomegaly and multiple liver lesions; the diagnosis was performed on specimens obtained from mediastinal mass. Bilateral bone marrow biopsy was negative for HL involvement. The stage was defined as IV B. He was treated from November to July 2000 with eight cycles according to ABVD schedule (doxorubicin, bleomycin, vinblastine and dacarbazine) achieving a complete remission (CR). The patient remained in good clinical condition until March 2009, and did not present ......
POSTED 08/27/2010 at 01:28 AM --
|
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib
Abstract: Imatinib induces several effects on the immune system, including hypogammaglobulinemia and has been associated with multiple myeloma in some patients. We studied the phenotype of plasma cells from patients with chronic myeloid leukemia (CML) undergoing therapy with Imatinib mesylate (Glivec). Bone marrow samples from 30 CML patients were evaluated and plasma cells were identified by multiparametric flow cytometry. In 21 patients an abnormal plasma cell phenotype, characterized by the absence of CD19, was registered, with 12 patients expressing also the CD56 molecule. A significant correlation between abnormal plasma cell phenotype and reduced γ-globulin levels was found. Immunofixation was always negative.Therapy with Imatinib for CML seems to induce a plasma cell phenotype with......
POSTED 08/27/2010 at 01:28 AM --
|
Current and Future Clinical Strategies in the Management of Chronic Myeloid Leukemia
Pharmacotherapy 30(9, part 2): 77S-101S Abstract Rational design of tyrosine kinase inhibitors, such as imatinib, against leukemogenic Bcr-Abl kinase has resulted in unprecedented responses and survival rates in patients with chronic myeloid leukemia (CML). Although these responses are sustained for years in the majority of patients, a fraction of the patients either fail or respond suboptimally to imatinib therapy, or are intolerant to the drug. Biologic insights into the mechanisms of imatinib resistance led to the development of several strategies, including dose escalation and second-generation tyrosine kinase inhibitors. Dasatinib and nilotinib are second-generation tyrosine kinase inhibitors that are approved as second-line treatment for imatinib-resistant patients based on their act......
POSTED 08/27/2010 at 12:52 AM --
|
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib
In conclusion, in IM-treated patients, absence of transcripts should not be interpreted as absence of the leukemic clone, although continuing IM after achievement of CMR may lead to further reduction of residual disease. Post-SCT, we found little evidence that the transcripts occasionally detected originate from the leukemic clone. (Source: Blood)...
POSTED 08/26/2010 at 11:02 AM --
|
Remission in CML: is DNA useful?
(Source: Blood)...
POSTED 08/26/2010 at 11:02 AM --
|
Analysis of BCRâABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype
Analysis of BCR–ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype
Leukemia advance online publication, August 26, 2010. doi:10.1038/leu.2010.179
Authors: H Grant, X Jiang, J Stebbing, L Foroni, C Craddock, M Griffiths, R E Clark, S O'Brien, J S Khorashad, G Gerrard, L Wang, J A E Irving, M Wang, L Karran, M J S Dyer, D Forrest, K Page, C J Eaves
& A Woolfson (Source: Leukemia)...
POSTED 08/25/2010 at 06:00 PM --
|
Why do Kinase Inhibitors Cause Cardiotoxicity and What can be Done About It?
Abstract: Cancer growth and metastasis are often driven by activating mutations in, or gene amplications of, specific tyrosine or serine/threonine kinases. Kinase inhibitors (KIs) promised to provide targeted therapyâspecifically inhibiting the causal or contributory kinases driving tumor progression while leaving function of other kinases intact. These inhibitors are of 2 general classes: (1) monoclonal antibodies that are typically directed against receptor tyrosine kinases or their ligands and (2) small molecules targeting specific kinases. The latter will be the focus of this review. This class of therapeutics has had some remarkable successes, including revolutionizing the treatment of some malignancies (eg, imatinib [Gleevec] in the management of chronic myeloid leukemia) and addin......
POSTED 08/24/2010 at 12:28 AM --
|
Older population missing out on life saving cancer drug
When it was approved by the FDA in 2001, imatinib, or GLEEVEC, was billed as a wonder drug that could help patients with chronic myeloid leukemia (CML), a fatal disease, live. (Source: bizjournals.com Health Care:Health Insurance headlines)...
POSTED 08/22/2010 at 11:00 PM --
|
Older population missing out on life saving cancer drug
When it was approved by the FDA in 2001, imatinib, or GLEEVEC, was billed as a wonder drug that could help patients with chronic myeloid leukemia (CML), a fatal disease, live. (Source: bizjournals.com Health Care:Biotechnology headlines)...
POSTED 08/22/2010 at 11:00 PM --
|
US Oncology Helps Deliver Latest Cancer Therapies
Through Local Community Access to Cutting Edge Research - New CML therapy is 42nd treatment to gain FDA approval as a result of clinical trials in part supported by physicians and patients in the US Oncology Research network. (Source: Disabled World)...
POSTED 08/19/2010 at 04:31 PM --
|
BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
Authors: Gonzalez MS, De Brasi CD, Bianchini M, Gargallo P, Moiraghi B, Bengió R, Larripa IB
BCR-ABL fusion gene is implicated in the pathogenesis of chronic myeloid leukemia (CML), encoding the oncoprotein p210(BCR-ABL) with anti-apoptotic activity. The inability to undergo apoptosis is an important mechanism of drug resistance and neoplastic evolution in CML. The gene transcript expression of mitochondrial apoptotic related genes BAX and BCL-XL was evaluated by quantitative Real Time PCR (qPCR) in vitro in K562 cells and in vivo in peripheral blood of 66 CML patients in different stages of the disease: 13 cases at diagnosis, 34 in chronic phase (CP), 10 in accelerated phase (AP) and 9 in blast crisis (BC). Our results in K562 cells showed that all treatments with different tyrosin......
POSTED 08/18/2010 at 06:00 PM --
|
Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform.
CONCLUSIONS: The HRM method developed here is an extremely sensitive, accurate and reliable technique and allows high-throughput, fast pre-screening to select for sequencing only those specimens that most likely contain mutant JAK2 V617F allele(s).
PMID: 20728437 [PubMed - as supplied by publisher] (Source: International Journal of Clinical Chemistry)...
POSTED 08/18/2010 at 06:00 PM --
|
Inhibition of Advanced Glycation End Product Formation by Medicinal Plant Extracts Correlates with Phenolic Metabolites and Antioxidant Activity
Planta MedDOI: 10.1055/s-0030-1250161AbstractNonenzymatic formation of advanced glycation end products (AGEs) is accelerated under hyperglycemic conditions characteristic of type 2 diabetes mellitus and contributes to the development of vascular complications. As such, inhibition of AGE formation represents a potential therapeutic target for the prevention and treatment of diabetic complications. In the present study, ethanolic extracts of 17 medicinal plants were assessed for inhibitory effects on in vitro AGE formation through fluorometric and immunochemical detection of fluorescent AGEs and Nε-(carboxymethyl)lysine adducts of albumin (CML‐BSA), respectively. Most extracts inhibited fluorescent AGE formation with IC50 values ranging from 0.4 to 38.6 µg/mL and all extrac......
POSTED 08/18/2010 at 12:52 AM --
|
Targeting autophagy to fight hematopoietic malignancies.
Authors: Puissant A, Robert G, Auberger P
Macroautophagy, referred hereafter to as autophagy is an evolutionary conserved catabolic process for the degradation and recycling of macromolecules, bulk cytoplasm and dammaged organelles. Autophagy is activated under stress conditions induced by nutrient deprivation, hypoxia and drug treatments. Morphologically, autophagic cells are characterized by the accumulation of double membrane cytoplasmic vesicules called autophagosomes that surrounds cytoplasmic proteins and/or organelles. Autophagosomes next fuse with lysosomes to generate autolysosomes, the structures in which the retained constituents are digested before recycling into the cytoplasm. In this context, autophagy promotes cell survival under adverse conditions. In contrast, under ce......
POSTED 08/17/2010 at 12:33 PM --
|
The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma.
Authors: Pasquali S, Mocellin S
Alpha interferons (IFN) are type I IFNs that have pleiotropic effects on cell functions. A wealth of evidence exists that these cytokines exhibit a variety of biological effects different from those on viral replication, including antitumor activity. IFNs-alpha represent the cytokines exhibiting the longest record of use in clinical oncology for the treatment of over a dozen of cancer types, including some hematological malignancies and solid tumors. Although targeted anticancer agents have recently replaced IFN-alpha in the treatment of certain hematological (e.g. chronic myeloid leukemia) and solid (e.g. renal cell carcinoma) malignancies, this cytokine is still used for the treatment of patients with specific tumor types, such as cutaneous melanoma. D......
POSTED 08/15/2010 at 06:00 PM --
|
Chronic myeloid leukemia: New lab test could identify imatinib resistance
Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia. (Source: ScienceDaily Headlines)...
POSTED 08/13/2010 at 04:00 PM --
|
Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma.
CONCLUSIONS: The high-throughput methods that were developed are suitable for the therapeutic drug monitoring of imatinib in plasma. They can be used in routine clinical practice.
PMID: 20713033 [PubMed - as supplied by publisher] (Source: International Journal of Clinical Chemistry)...
POSTED 08/12/2010 at 06:00 PM --
|
Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response
(Source: Blood)...
POSTED 08/12/2010 at 11:01 AM --
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE:
The information provided on this site is intended for your general knowledge only and is not a substitute for professional
medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a
qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.
|
|
|
|
|
|
|
|
Featured Product! |
 |
|
Arthrit-Eze |
|
Arthrit-Eze is the most advanced
formula on the market today |
|
It offers potential relief and
rejuvenation for all forms of arthritis, safely, naturally and without side
effects!
NO PRESCRIPTION REQUIRED! |
|
CLICK HERE
for more info... |
|
|
